Intraovarian platelet-rich plasma (PRP) infusion appeared to benefit low prognosis IVF patients; however, when compared to controls, no significant benefit could be confirmed

Purpose: To assess whether in-office intraovarian PRP injections among patients with a history of a low euploid embryo yield following freeze-all PGT-A IVF cycle improves transferable embryo yield when compared to controls. Materials and methods: A retrospective case–control study, between March 2022 and December 2024 where all poor outcome patients who underwent in-office intraovarian PRP injection prior to a repeat freeze-all PGT-A IVF cycle were compared to controls with no intervention between cycles. The primary outcome was transferable embryo yield. Secondary outcomes included: blastocyst yield, aneuploidy rate, and euploid yield. Results: Thirty-two patients met the inclusion criteria and were compared to 309 controls. Mean age for the PRP and control group were 38.3 ± 3.1 and 38.4 ± 3.7 (p = 0.91) respectively. Mean AMH for the PRP group was 1.6 ± 1.1 ng/mL as compared to 1.5 ± 1.0 ng/mL (p = 0.34). Following PRP the blastocyst, euploid and transferable embryo yield increased; however, when compared to controls, there were no differences in IVF outcomes. For patients with an AMH ≥ 1, the euploid yield and transferable embryo yield increased by fivefold; however, there was no difference when compared to the control. For patients with an AMH < 1, there were no differences in euploid or transferable embryo yield following PRP. Conclusion: Although there was an improvement in transferable embryos yielded following PRP, no difference was observed compared to the control group, as the control with a poor initial cycle experienced regression to the mean which may also be a source of bias in the PRP group.